MRSN
Mersana TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
MRSN Profile
Mersana Therapeutics, Inc.
A clinical-stage biopharmaceutical company that developing antibody drug conjugates to cure various cancers
840 Memorial Drive, Cambridge, MA 02139
--
Mersana Therapeutics, Inc., was incorporated in Delaware in February 2002 under the name Nanopharma Corp. In November 2005, they changed their name to Mersana Therapeutics, Inc. The Company is a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates, or ADCs, that provide clinically meaningful benefits to cancer patients with significant unmet needs. The company leverages 20 years of industry learning in the ADC field to develop proprietary technologies that enable designed ADCs to have better efficacy, safety and tolerability relative to existing ADC therapies. In addition, the Company entered into a strategic partnership with Takeda Pharmaceutical Company Limited or Takeda, whereby the Company acquired the rights to the XMT-1522 outside the United States and Canada. The company also has strategic R&D partnerships with Takeda and Merck KGaA for the development and commercialization of additional ADC product candidates for a limited number of targets selected by partners based on their Dolaflexin platform.
